AMRN [NASD]
Amarin Corporation plc
Index- P/E- EPS (ttm)-0.06 Insider Own0.40% Shs Outstand397.81M Perf Week15.20%
Market Cap479.65M Forward P/E- EPS next Y-0.16 Insider Trans0.91% Shs Float381.31M Perf Month-54.43%
Income-22.20M PEG- EPS next Q-0.06 Inst Own36.70% Short Float4.74% Perf Quarter-57.01%
Sales535.60M P/S0.90 EPS this Y140.70% Inst Trans4.14% Short Ratio4.53 Perf Half Y-65.13%
Book/sh1.61 P/B0.89 EPS next Y700.00% ROA-2.20% Target Price3.61 Perf Year-68.49%
Cash/sh1.09 P/C1.32 EPS next 5Y38.90% ROE-3.40% 52W Range1.11 - 5.97 Perf YTD-57.27%
Dividend- P/FCF- EPS past 5Y15.40% ROI1.00% 52W High-75.88% Beta2.29
Dividend %- Quick Ratio1.70 Sales past 5Y35.00% Gross Margin78.50% 52W Low29.73% ATR0.18
Employees560 Current Ratio2.60 Sales Q/Q-33.50% Oper. Margin-3.10% RSI (14)30.15 Volatility11.49% 9.19%
OptionableYes Debt/Eq0.00 EPS Q/Q- Profit Margin-4.10% Rel Volume0.67 Prev Close1.47
ShortableYes LT Debt/Eq0.00 EarningsMay 04 BMO Payout- Avg Volume4.00M Price1.44
Recom2.30 SMA20-30.20% SMA50-48.10% SMA200-62.69% Volume2,708,387 Change-2.04%
May-06-22Downgrade JP Morgan Neutral → Underweight
May-05-22Downgrade SVB Leerink Outperform → Mkt Perform $10 → $3
May-05-22Downgrade H.C. Wainwright Buy → Neutral $10 → $3
May-04-22Downgrade Northland Capital Outperform → Market Perform
May-12-21Downgrade Goldman Neutral → Sell $6 → $5
Sep-29-20Resumed JP Morgan Neutral
Aug-26-20Initiated Piper Sandler Overweight $21
May-05-20Initiated Northland Capital Outperform $15
Mar-31-20Upgrade Oppenheimer Underperform → Perform
Mar-31-20Downgrade Jefferies Buy → Hold $30 → $4
Mar-31-20Downgrade Goldman Buy → Neutral
Mar-13-20Upgrade Goldman Neutral → Buy $28
Mar-02-20Initiated Cowen Outperform $23
Feb-18-20Upgrade Citigroup Neutral → Buy $27 → $24
Jan-06-20Initiated JP Morgan Neutral $22
Dec-16-19Downgrade Stifel Buy → Hold
Nov-20-19Initiated Oppenheimer Underperform $7
Nov-18-19Downgrade Citigroup Buy → Neutral
Nov-15-19Reiterated SVB Leerink Outperform $26 → $29
Oct-31-19Initiated Aegis Capital Buy $23
May-19-22 08:23AM  
May-16-22 08:00AM  
May-13-22 06:34AM  
May-12-22 08:00AM  
May-05-22 11:30AM  
May-04-22 07:30PM  
10:51AM  
07:00AM  
May-03-22 08:00AM  
Apr-26-22 08:49AM  
Apr-19-22 07:30AM  
Apr-01-22 07:00AM  
Mar-31-22 10:06AM  
Mar-28-22 07:00AM  
Mar-21-22 08:30AM  
Mar-10-22 08:47AM  
Mar-02-22 10:29AM  
Mar-01-22 01:00PM  
06:00AM  
Feb-25-22 08:00AM  
Feb-24-22 07:30AM  
Feb-15-22 08:00AM  
Feb-01-22 05:38PM  
Jan-31-22 05:38PM  
Jan-28-22 08:23AM  
Jan-18-22 08:15AM  
Jan-12-22 12:11PM  
09:38AM  
Jan-10-22 07:00AM  
Jan-04-22 07:00AM  
04:10AM  
Dec-27-21 06:09AM  
Dec-22-21 04:00PM  
07:00AM  
Dec-21-21 09:41PM  
06:38PM  
05:17PM  
03:45PM  
Dec-20-21 09:50AM  
Dec-19-21 07:29PM  
Dec-17-21 06:19PM  
11:45AM  
Dec-16-21 06:30PM  
04:00PM  
09:30AM  
Dec-15-21 05:37PM  
01:15PM  
Dec-14-21 09:00PM  
06:20PM  
12:00PM  
10:00AM  
09:50AM  
Dec-13-21 10:15PM  
01:30PM  
Dec-10-21 03:05PM  
Dec-09-21 09:00PM  
08:45PM  
04:30PM  
02:55PM  
11:00AM  
Dec-08-21 10:35AM  
08:42AM  
Dec-07-21 11:34PM  
05:03PM  
02:15PM  
01:38PM  
Dec-06-21 02:30PM  
09:35AM  
Dec-03-21 07:44PM  
05:26AM  
Dec-02-21 11:32PM  
09:15PM  
07:45PM  
Nov-30-21 07:31PM  
06:01PM  
11:58AM  
10:00AM  
Nov-29-21 09:35PM  
05:19AM  
05:00AM  
Nov-28-21 07:09PM  
Nov-27-21 09:35PM  
Nov-26-21 10:05AM  
Nov-25-21 11:32PM  
11:00AM  
Nov-24-21 03:17PM  
Nov-22-21 10:00PM  
05:40AM  
Nov-21-21 10:45PM  
Nov-19-21 03:45PM  
03:15PM  
11:15AM  
10:00AM  
Nov-18-21 07:00PM  
06:21PM  
05:25PM  
04:30PM  
12:45PM  
Nov-17-21 06:45PM  
05:59PM  
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Zakrzewski Joseph SDirectorDec 15Buy3.152,0006,310196,547Dec 16 08:01 PM
Zakrzewski Joseph SDirectorDec 14Buy3.2710,00032,689194,547Dec 16 08:01 PM
Kalb Michael WayneSVP and CFOAug 12Option Exercise2.35120,000281,800325,010Aug 13 08:04 PM
Kalb Michael WayneSVP and CFOAug 12Sale5.25120,000630,240205,010Aug 13 08:04 PM
STACK DAVID MDirectorJun 04Buy4.5410,00045,35040,000Jun 07 09:53 PM
STACK DAVID MDirectorJun 03Buy4.625,00023,11530,000Jun 07 09:53 PM